Stephania tetrandra and Its Active Compound Coclaurine Sensitize NSCLC Cells to Cisplatin through EFHD2 Inhibition
<i>S. tetrandra</i> and its active compound coclaurine may serve as effective adjuvant therapies to improve cisplatin efficacy in the treatment of NSCLC.
Authors
- Shu-Yu Hu
- Wei‐Chao Chang (ORCID: https://orcid.org/0000-0003-1669-0037)
- Wei‐Chien Huang (ORCID: https://orcid.org/0000-0001-6467-8716)
- Tsai-Hui Lin
- Yuhao He (ORCID: https://orcid.org/0000-0001-6355-3006)
- Chung‐Yu Chen (ORCID: https://orcid.org/0000-0002-1725-0079)
- Ching-Yun Hsieh
- Ya-Huey Chen
Institutions
- China Medical University (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-10-11
- DOI
- https://doi.org/10.3390/ph17101356
- Citations
- 4
- Primary Topic
- Berberine and alkaloids research
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- China Medical University Hospital
- China Medical University
- National Science and Technology Council
- Division of Materials Research